Recent clinical studies have demonstrated that NSCLC patients harboring tumor driver genes such as EGFR mutations40 or ALK rearrangement/fusion41 are more prone to developing metastases beyond the primary tumor site. This evidence concerns the gene EGFR and neoplasm.